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Background: We aimed to investigate the correlation of maximum standardized uptake value (SUVmax) with
pathological characteristics of primary tumor and to determine a Tumor/ Lymph node (T/LN) SUVmax ratio
predicting metastasis to lymph nodes in NSCLC patients.
Methods: Eighty-one NSCLC patients who had PET/CT examination at initial staging and subsequently underwent
surgical resection were retrospectively evaluated. There were 100 PET/CT positive mediastinal or hilar lymph node
stations. Pathological characteristics of the tumor such as largest tumor diameter, tumor histology, differentiation,
number of mitosis, degree of stromal inflammation, necrosis; etiology of PET/CT positive lymph node stations;
SUVmax of primary tumor and positive lymph node stations were recorded. A T/LN SUVmax ratio was calculated for
each lymph node station.
Results: SUVmax of the primary tumor was positively correlated with the largest tumor diameter (p = 0.001,
r = 0.374), number of mitosis (p < 0.001, r = 0.405), and postoperative pathological stage (p = 0.007, r = 0.298).
Patients with squamous cell carcinoma had a statistically significant higher mean SUVmax, number of mitosis and
advanced N stages compared to adenocarcinoma. The etiology of 100 PET/CT positive lymph node stations were
metastasis in 14, anthracosis in 40, reactive in 39, granulomatous in 4, and silicosis in 3 patients. A T/LN SUVmax
ratio of 5 or lower was suggestive for a malignant lymph node with a sensitivity of 92.8% and specificity of 47%.
Conclusions: SUVmax of a primary tumor is related to certain pathological characteristics, such as largest diameter,
histology, and number of mitosis. A T/LN SUVmax ratio lower than 5 predicts the metastasis to lymph nodes with a
high sensitivity.* Correspondence: dckoksal@gmail.com
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Non-small cell lung cancer (NSCLC) is a heterogeneous
group of carcinomas with different biological behaviors
and prognoses. Histological classification and staging are
critical in constituting a treatment strategy and predicting
prognosis for NSCLC [1]. [18 F]-2-fluoro-deoxy-D-glucose
(FDG)-positron emission tomography (PET) is a metabolic
imaging technique which has become an essential tool for
staging of NSCLC patients. The integration of PET with
computed tomography (PET/CT) provides an accurate
anatomic localization and improved staging especially for
mediastinal lymph nodes and occult distant metastases
[2,3]. It also provides prognostic information, monitors
response to therapy and can be used to follow up patients
after treatment [4]. The rationale for using FDG-PET in
oncology is its ability to measure increased glucose metab-
olism of tumor cells. Elevated FDG uptake suggests that
the lesions or tissues harbor tumor cells. The maximum
standardized uptake value (SUVmax) greater than 2.5 is
often used as a cut off value for malignancy. However it
has been shown that there is a significant number of false
positivity (due to inflammatory diseases) and false negativ-
ity (due to low-grade malignancies) in the evaluation of
primary tumor [5]. The major reasons of false negative
and false positive lymph nodes are microscopic metastasis
beyond the spatial resolution of PET/CT and lymph node
involvement by underlying inflammatory processes such
as immune reaction due to the presence of lung tumor,
obstructive pneumonia, anthracosis or granulomatous
inflammation [6-8].
It is often assumed that FDG uptake is primarily
within the malignant tumor cells, and SUVmax is a well
known measure indicating the aggressiveness of tumor
[9,10]. But other cellular components of such as normal
parenchymal cells, atypical cells, inflammatory cells,
fibroblasts, or hematopoietic progenitor cells may also
uptake FDG. To the best of our knowledge, there is only
one study investigating the correlation between SUVmax
and specific cellular components of the tumor conducted
in patients with resected stage 1 NSCLC. In that study
the authors found that the cellular composition of the
tumor was highly variable and there wasn’t any correl-
ation between a specific tumor cellular component and
FDG activity [11].
SUVmax of the primary tumor is a risk factor for
occult mediastinal metastasis in clinical stage 1 NSCLC
patients [12-14]. The likelihood of lymph node metasta-
sis increases with the increase of tumor SUVmax [6,15].
SUVmax of lymph node is also important for predicting
metastasis, but false positivity is an important challenge
[6,7]. For this reason some authors claimed to use a
higher SUVmax value instead of the traditional value of
2.5 in order to increase the accuracy for presence of
metastasis [7].In this study we aimed to investigate the correlation of
tumor SUVmax value with largest tumor diameter, tumor
histology, differentiation, number of mitosis, degree of
stromal inflammation and necrosis, and to determine
whether a T/LN SUVmax ratio can predict the presence




Eighty-one chemotherapy and/or radiotherapy naive
NSCLC patients with a PET/CT examination at the
time of initial staging who subsequently underwent sur-
gical resection were retrospectively evaluated. Among
them 77 were male and 4 were female with a mean age
of 59.8 ± 8 years (range: 38-74). Fifty-five patients
underwent lobectomy, 25 patients pneumonectomy and
1 patient wedge resection with complete ipsilateral hilar
and mediastinal lymph node dissection. Pathological
stage was determined according to 7th edition of TNM
staging system [1]. Demographic data of the patients,
histopathological diagnosis, T and N stages are presented
in Table 1. This retrospective study was approved by
Institutional Review Board Committee.
PET/CT imaging
PET/CT was carried out with an integrated PET/CT scan-
ner (Siemens, Biograph-6- True Point) within the 30 days
before the surgery in all of the patients. Patients were
instructed to fast for at least 6 hours before the examin-
ation. After confirmation of a normal peripheral blood
glucose level (<180 mg/dL), the patients received an intra-
venous injection of 145 μCi/kg (maximum 200 μCi) of
FDG and rested for 60 minutes before the scan. Images
were obtained from the base of skull to mid-thigh level.
The SUVmax of the primary tumors and each suspicious
lymph node stations were determined automatically by
the software after delination of the region of interest on
attenuation-corrected PET/CT images.
All PET/CT scans were reevaluated. SUVmax of the
primary tumors and dissected mediastinal and hilar
lymph node stations were noted. Lymph node stations
were considered as positive if there was a FDG uptake
higher than the surrounding mediastinal blood pool.
The SUVmax value of positive lymph node stations
were ranging between 1.57 and 24.75 (median: 3.15,
mean ± SD: 3.57 ± 2.45). Tumor/ lymph node SUVmax
(T/LN SUVmax= tumor SUVmax/ lymph node station
SUVmax) ratio was calculated for each lymph node station.
Pathological evaluation
All prepared hematoxylin-eosin stained slides of each
resected tumor and lymph nodes were re-evaluated by an
experienced pulmonary pathologist blinded to PET/CT
Table 1 Patient characteristics
Characteristic Number of patients (%)
Male/Female 77 male/4 female
Mean age (years) 59.8 ± 8 (range: 38-74)
Type of surgery
Lobectomy + LND 55 (67.9%)
Pneumonectomy + LND 25 (30.9%)
Wedge resection + LND 1 (1.2%)
Tumor histology
Adenocarcinoma 32 (39.5%)
Squamous cell carcinoma 43 (53.1%)
Adenosquamous carcinoma 4 (4.9%)
Pleomorphic carcinoma 2 (2.5%)
Adenocarcinoma classification
Acinar predominant 16 (50%)
Solid predominant 9 (28.1%)
Papillary predominant 3 (9.4%)
Lepidic predominant 2 (6.2%)
Minimally invasive mucinous 2 (6.2%)
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logical subtype and the largest primary tumor diameter
were noted. Invasive adenocarcinomas (AC) were classi-
fied according to the new adenocarcinoma classification
using the predominant histology in a tumor, as lepidicpredominant, acinar predominant, papillary predominant,
micropapillary predominant, and solid predominant with
mucin production [16]. The differentiation of squamous
cell carcinomas (SCC) was noted. All of the slides of the
tumor were evaluated for the number of mitosis, presence
of necrosis, and stromal inflammation. Number of mitosis
was counted in the 10 consecutive high power field with-
out necrosis. Necrosis was graded as “0” if there wasn’t
any necrosis in all the slides, “1” if there was necrosis in
only one slide, “2” if there was necrosis in two slides, and
“3” if there was necrosis in more than two slides. Stromal
inflammation was graded semi-quantitatively as mild,
moderate, and severe.
Three hundred and thirty-four lymph node (mediastinal
and hilar) stations from 81 patients were reevaluated for
the presence of metastasis. The number of lymph nodes in
each station was not noted. Interlobar and intrapulmonary
lymph nodes were excluded. PET positive lymph node sta-
tions (n = 100) were investigated for the presence of react-
ive lymphoid proliferation, anthracosis, granulomatous
reactions, and silicotic nodules [17].
Statistical analysis
SPSS for windows release 19.0 package program was
used to carry out the statistical analysis and construct
figures. The descriptive analysis was expressed in terms
of frequency, median, mean and standart deviation.
Comparisons of ordinal parameters between different
groups were performed by Chi-square test. Compari-
sons of continuous parameters between different groups
were performed by nonparametric Mann Whitney-U
and Kruskal-Wallis test. Spearman’s rank correlation
was performed to analyze the correlation between vari-
ables, such as SUVmax, largest tumor diameter, number
of mitosis, degree of necrosis and stromal inflammation.
Receiver operating characteristics (ROC) curve analysis
was generated that maximized the sensitivity and the
specificity and thus the accuracy for assessing a cut off
value for T/LN SUVmax ratio. A p value less than 0.05
was considered to be statistically significant.
Results
Evaluation of the primary tumor
The pathological characteristics and mean SUVmax of the
tumors are shown in Table 2. Mean diameter of the tu-
mors were 4.86 ± 1.93 cm (range: 1.5-10). Mean SUVmax
of the tumors were 14.23 ± 7.23 (range: 2.23-38.76). Mean
number of mitosis, median degree of necrosis and stromal
inflammation were 27.9 ± 17.2 (range: 2-80), 1 (range: 0-3)
and 2 (range: 1-3), respectively.
SUVmax of the tumors were positively correlated with
the number of mitosis (p < 0.001, r = 0.405) (Figure 1).
There was no correlation between the tumor SUVmax
and degree of stromal inflammation (p = 0.381) or degree
Table 2 Tumor characteristics
Characteristic
Mean tumor diameter 4.86 ± 1.93 cm (range: 1.5-10)
Mean tumor SUVmax 14.23 ± 7.23 (range: 2.23 ± 38.76)







Median grade of necrosis 1 (range: 0-3)




Median grade of stromal inflammation 2 (range: 1-3)
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with the tumor diameter (p = 0.001, r = 0.374). The diam-
eter of the tumors were positively correlated with the
degree of necrosis (p < 0.001, r = 0.521).
The pathological stage of the disease was positively
correlated with the tumor diameter (p < 0.001, r = 0.503),
SUVmax (p = 0.007, r = 0.298), number of mitosis
(p = 0.038, r = 0.231) and the degree of necrosis (p = 0.002,
r = 0.335). T stage was positively correlated with the
tumor diameter (p < 0.001, r = 0.725), SUVmax (p = 0.005,
r = 0.309), number of mitosis (p = 0.048, r = 0.220) and
the degree of necrosis (p < 0.001, r = 0.412). There was
no correlation between the N stage and tumor SUVmax



















Figure 1 There was a positive correlation between tumor
SUVmax and number of mitosis (p < 0.001, r = 0.405).Tumor characteristics of AC and SCC were compared
in Table 3. Two groups had a similar T stage (p = 0.25).
N stages were advanced in SCC (p = 0.017). Tumor
SUVmax (p = 0.042) and number of mitosis (p < 0.001)
were significantly higher in SCC. Tumor diameter was
positively correlated with the SUVmax of the tumor
both in the AC (p = 0.003, r = 0.508) and SCC patients
(p = 0.002, r = 0.453). We also compared the tumor
SUVmax/ tumor diameter ratios in order to eliminate
the effect of tumor diameter on SUVmax and showed
that SCC had a significantly higher ratio (p = 0.006).
According to the new AC classification, the study group
consists of 16 acinary, 9 solid, 3 papillary, 2 lepidic, and 2
mucinous AC patients (Table 1). We only compared
acinary AC with solid AC because of low number of cases
in the last three groups (Table 4). Mean tumor diameter
(p = 0.014), number of mitosis (p = 0.018) and grade of
necrosis (p = 0.001) were significantly higher in solid AC.
Although the tumor SUVmax was higher in solid AC, it
did not reach a statistical significance. We also compared
the tumor SUVmax/ tumor diameter ratios and found no
difference between acinary and solid AC (p = 0.73).
The differentiation of SCC is shown in Table 1. There
was no correlation between the differentiation of the tumor
and SUVmax (p = 0.61), number of mitosis (p = 0.9), degree
of necrosis (p = 0.2). Stromal inflammation was higher in
poorly differentiated SCC (p = 0.03, r = 0.31).
Evaluation of the lymph nodes
A total of 334 mediastinal and hilar lymph node stations
were evaluated. Among them, there were 100 lymph
node stations showing higher FDG uptake than the
surrounding mediastinal blood pool (SUVmax range:
1.57-24.75, median: 3.15, mean ± SD: 3.57 ± 2.45) on
PET/CT. Fourteen (14%) of them were due to metasta-
sis, 39 (39%) reactive, 40 (40%) anthracosis, 4 (4%)
granulomatosis and 3 (3%) silicosis. All of the metastaticTable 3 The comparison of tumor characteristics of








4.9 ± 2.2 4.7 ± 1.6 0.93
Tumor SUVmax (mean ± SD) 12.6 ± 8.3 15 ± 5.9 0.042*
Number of mitosis
(mean ± SD)
16.12 ± 12.03 31.5 ± 18.0 <0.001*





diameterÞ (mean ± SD)
2.64 ± 1.52 3.50 ± 1.71 0.006*
*Statistically significant.
Þ In order to eliminate the effect of tumor diameter on the SUVmax values,
we compare the tumor SUVmax value/ tumor diameter ratios.
Table 4 The comparison of tumor characteristics of






Tumor diameter (cm) (mean ± SD) 4.7 ± 1.8 6.8 ± 2.1 0.014*
Tumor SUVmax (mean ± SD) 12.9 ± 7.5 16.7 ± 8.1 0.21
Number of mitosis (mean ± SD) 12.8 ± 7.1 26.7 ± 15.4 0.018*
Necrosis (median) 1 2 0.002*
Stromal inflammation (median) 2 2 0.48
Tumor SUVmax/Tumor diameter¥
(mean ± SD)
2.90 ± 1.49 2.63 ± 1.44 0.73
*Statistically significant.
¥ In order to eliminate the effect of tumor diameter on the SUVmax values,
we compare the tumor SUVmax value/ tumor diameter ratios.







Tumor SUVmax 15.26 ± 6.02 16.5 ± 6.83 0.49
Lymph node SUVmax 5.35 ± 5.72 3.28 ± 1.19 0.06
T/LN SUVmax 3.73 ± 1.49 5.66 ± 3.32 0.01*
*Statistically significant.
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SUVmax ≥2.5. Twenty-four patients (29.6%) had meta-
static interlobar or intrapulmonary lymph nodes that
could not be identified on PET/CT because of close
relationship with the primary tumor.
PET/CT evaluation and the presence of metastasis in
the mediastinal and hilar lymph node stations are shown
in Table 5. The sensitivity, specificity, and accuracy of
PET/CT for the staging of mediastinal and hilar lymph
nodes were 63.6%, 72.4%, and 71.8% respectively. False
positive and false negative lymph node ratios were 86%
and 3.4%, respectively.
Metastatic and non-metastatic lymph node stations
are compared in Table 6. Mean lymph node SUVmax
was higher in the metastatic lymph nodes, but did not
reach statistical significance (p = 0.06). T/LN SUVmax
ratios were significantly lower in the metastatic lymph
nodes (p = 0.01). The comparison of metastatic, anthracotic
and reactive lymph nodes are seen in Table 7. Mean LN
SUVmax (p = 0.04) and T/LN SUVmax ratios (p = 0.02)
were significantly different among the groups. Mean LN
SUVmax (p = 0.12) and T/LN SUVmax ratios (p = 0.29) of
the anthracotic and reactive lymph nodes were similar.
Metastatic lymph nodes had a significantly higher mean LN
SUVmax (p = 0.018) and significantly lower T/LN SUVmax
ratios (p = 0.006) compared to anthracotic LN. Mean LN
SUVmax was higher in the metastatic lymph nodes
compared to reactives but the difference did not reach
to statistical significance (p = 0.15). T/LN SUVmax ratiosTable 5 The PET/CT evaluation and presence of
metastasis in mediastinal and hilar lymph node stations
PET/CT Metastasis (+) Metastasis (-) Total
Positive§ 14 86 100
Negative 8 226 234
Total 22 312 334
§A quantifiable SUVmax value is considered as positive.
-The sensitivity of PET/CT: 63.6%, the specificity of PET/CT: 72.4%.
-False positive lymph node ratio 86%, false negative lymph node ratio 3.4%.were significantly lower (p = 0.034) in the metastatic lymph
nodes compared to reactive LN.
A T/LN SUVmax ratio of 5 or lower was suggestive
for a malignant lymph node with a sensitivity of 92.8%
and a specificity of 47% (p = 0.01) (Figure 2).Discussion
The present study revealed that SUVmax of the primary
tumor is positively correlated with the largest tumor
diameter, number of mitosis, and pathological stage of
the disease. Mean SUVmax and number of mitosis were
higher in SCC compared to AC. N stages were advanced
in SCC. Reactive hyperplasia and anthracosis were the
major etiologies for positive lymph nodes on PET/CT.
A T/LN SUVmax ratio of 5 or lower was suggestive for
a malignant lymph node with high sensitivity (92.8%)
but low specificity (47%).
FDG activity in other words SUVmax measured on
PET/CT is a semiquantitative value that indicates the de-
gree of glucose uptake in a lesion. The exact mechanism
of FDG uptake remains unknown. Most lung cancers
accumulate FDG preferentially that SUVmax may vary
widely [11,18]. SUVmax of a tumor is a product of several
fundamental factors including glucose metabolism and
the type/number of cells present in the tumor. Higher
SUVmax may be a result of either higher mitotic activity
of tumor cells or higher number of inflammatory cells
(lymphocytes, macrophages) that competitively uptake
FDG-glucose. Alternatively, there may be a large number
of tumor cells with low metabolic activity or a low number
of tumor cells with high metabolic activity [11]. In the
present study, we found a positive correlation between









Tumor SUVmax 15.26 ± 6.02 16.28 ± 6.95 17.0 ± 7.24 0.78
Lymph node SUVmax 5.35 ± 5.72 2.98 ± 0.86 3.36 ± 1.09 0.04*
T/LN SUVmax 3.73 ± 1.49 5.70 ± 2.79 5.38 ± 2.8 0.02*
*Statistically significant.
-Tumor SUVmax, Lymph node SUVmax and T/LN SUVmax ratios were similar in
antracotic and reactive lymph nodes (p > 0.05).
Figure 2 The receiver operating characteristics (ROC) curve for
the optimal cut off value for tumor/lymph node SUVmax ratios.
Area under the curve: 0.716; 95% confidence interval: 0.584 to 0.847;
p = 0.01. A T/LN SUVmax ratio of 5 or lower suggest a lymph node
to be malignant with a sensitivity of 92.8% and specificity of 47%.
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uptake. There was no correlation between tumor SUVmax
and the degree of stromal inflammation.
The tumor size and the presence of necrosis are other
factors that affect the SUVmax of a tumor. Previous
studies demonstrated the positive correlation between
tumor diameter and SUVmax [19-22]. The increase in
the tumor diameter was also correlated with more
glucose transporter-1 (Glut-1) expression on the surface
of tumor cells, leading to increased FDG uptake [23]. In
this study, the largest tumor diameter was positively
correlated with SUVmax in AC, SCC and the whole
study group. As expected, larger tumors were more nec-
rotic. Contrary to the conventional wisdom that tumor
necrosis dilutes standart uptake value, more necrosis
was not associated with lower SUVmax. There was no
correlation between SUVmax and the degree of necro-
sis. This condition can be explained by the fact that
SUVmax is calculated from the highest FDG uptake
regions of the tumor.
Consistent with the previous studies [6,19,21,22,24],
this study revealed that SCC had higher SUVmax values
compared to AC. This can be explained in two ways.
First, SCCs are rapidly growing tumors with shorter
doubling times, thus leading to higher levels of glucose
metabolism [18]. Second, the expression of Glut-1 is
higher in SCCs. The localization of Glut-1 is also
important in the uptake process of FDG. While Glut-1 is
mainly located in cytoplasm of tumor cells in ACs, it is
mainly located on cell membranes of tumor cells in
SCCs. The cell membrane localization is more important
in FDG uptake process [25,26].
Recently, a study investigating Glut-1 expression and
FDG uptake in histological subtypes of pulmonary ACdocumented that solid predominant ACs had a signifi-
cantly higher Glut-1 expressions and SUVmax than those
with other predominant histology [27]. In the present
study, despite the fact that there are limited number of
cases in AC subgroups, we compared solid predominant
ACs (n = 9) with acinary predominant ACs (n = 16 cases)
and found that the largest tumor diameters, number of
mitosis, and the degree of necrosis were higher in solid
ACs. Mean tumor SUVmax was also higher in solid pre-
dominant ACs but the difference did not reach statistical
significance. All these findings supported the aggressive
behavior of solid predominant ACs.
The relationship between tumor SUVmax and differen-
tiation is conflicting in the literature. Some studies showed
that tumor SUVmax was higher in poorly differentiated
NSCLCs [22,28]. Another study found no correlation be-
tween SUVmax and the degree of differentiation in SCCs
[19]. In the present study, there was no relation between
tumor SUVmax and differentiation in SCCs. But the de-
gree of stromal inflammation was higher in poorly differ-
entiated tumors.
Higher SUVmax of the primary tumor is found to be a
strong predictor of lymphtic vessel invasion and lymph
node metastasis in studies consisting resected early stage
NSCLC patients [21,29]. In a study conducted on a small
group of resected lung cancer patients, the authors in-
vestigated the correlation of SUVmax with the likelihood
of lymph node metastasis and reported that, when the
SUVmax of the primary tumor was greater than 12, the
probability of lymph node metastasis was high, reaching
70%, irrespective of the degree of FDG activity in the
lymph node stations [6]. In the present study, tumor
SUVmax was correlated with pathological T stage, dis-
ease stage, but not with N stage. Mean tumor SUVmax
was not different in patients with and without metastatic
lymph nodes (Table 6). Contrary to the current literature
reporting AC histology as a risk factor for occult N2
lymph node metastasis [12,13], in this study N stages
were advanced in SCCs that have higher SUVmax
compared to ACs.
PET/CT is now regarded as the most accurate im-
aging modality in N-staging of lung cancer. However
there are a significant number of false positivity and
false negativity. The major reason for false negativity is
microscopic metastasis beyond the spatial resolution of
PET/CT. The major reasons for false positivity are
lymph node involvement by underlying inflammatory
disease (tuberculosis, histoplasmosis), lymphadenopa-
thies secondary to obstructive pneumonia, immune
reaction due to the presence of lung tumor, antracosis,
and silicotic nodules [6,8]. The major cause of false
positivity may vary from region to region. In a study
from Alabama, histoplasmosis infection was the most
common cause of false positivity [7]. Silicosis has been
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Germany [30]. In the present study, there were
antracosis in 40% of the PET/CT positive lymph nodes
probably due to the intensive indoor air pollution or
biomass exposure. Granulomatous inflammation (4%)
and silicosis (3%) was low.
In the present study, distinctively from the literature, we
considered a lymph node station as positive if there was a
FDG uptake higher than the surrounding mediastinal
tissue, with regard to the idea that a tumor with low FDG
activity might have a metastatic lymph node with low FDG
activity. Thus we set a low threshold (any FDG uptake
higher than the surrounding mediastinal blood pool) in
order to avoid false negative lymph nodes and accept a
higher incidence of false positives. All of the metastatic
lymph nodes had a SUVmax higher than 2.5. The sensitiv-
ity (63.6%) and specificity (72.4%) of PET/CT was lower
than the current literature due to the lower threshold we
choose for PET/CT positivity.
In the present study we hypothesized that a T/LN
SUVmax ratio could be a predictor of lymph node metasta-
sis. This hypothesis was constituted based on the clinical
observation that a cut off value of 2.5 for the prediction
of metastasis is too low in countries where inflamatory
reactions are more prevelant. Besides in clinical practice we
realized that some tumors with low SUVmax values have
metastatic lymph nodes after resection despite lower
SUVmax values than 2.5 on PET/CT obtained before
surgery. The present study favors this hypothesis. As dem-
onstrated in Table 6, while mean SUVmax values were not
different between metastatic and non metastatic lymph
nodes, T/LN ratios were significantly lower in metastatic
ones. T/LN SUVmax ratios were similar in anthracotic and
reactive lymph nodes. A T/LN SUVmax ratio of 5 or lower
was suggestive for a malignant lymph node with high
sensitivity but low specificity. Since this study is performed
in a population where the prevalance of inflammatory
disease is high, T/LN SUVmax ratios may show variations
in different patient populations.
In the literature Cerfolio et al also determined a ratio
of LN/T SUVmax as a universal predictor of lymph node
metastasis in order to eliminate the variation of SUVmax
among different PET scanners, and documented that
when the ratio is 0.56 or greater, there is a 94% chance
that the node is malignant [31].
There are some limitations of the present study. First it
is a retrospective study with limited number of patients.
The study population consists of patients who underwent
surgery only that may cause a selection bias. Since all cases
were early lung cancers who are candidates for curative
surgery, the number of metastatic lymph nodes was low.
Prospective studies including more lymph node stations
are needed to examine the validation of a T/LN SUVmax
ratio for prediction of metastasis.Conclusions
In conclusion, SUVmax of a primary tumor is related to
certain pathological characteristics, such as largest diam-
eter, histology, and number of mitosis. A T/LN SUVmax
ratio lower than 5 predicts the metastasis to lymph nodes
with a high sensitivity.
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